Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study

Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized patients with severe pneumonia requiring oxygen supply and followed up for 6 months after hospital discharge (see primary and secondary outcomes).

Secondary objectives

To describe pulmonary sequelae according to :

• the unit in which the patient was hospitalized,
• the maximum oxygen flow rate required during hospitalization,
• McCabe score,
• age,
• tobacco consumption,
• biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),
• number of days from onset of symptoms to hospitalization,
• co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild to moderate COPD/respiratory failure, overweight),
• concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, ACE inhibitors)
• specific drug treatments administered to treat COVID-19 infection,
• non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment) to manage respiratory disorders of COVID-19 infection.

To assess the impact of factors of social inequality on the severity of COVID-19 infection.